Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 5, 2012, Pages

  Zong, Haihong ^a   Armoni, Michal ^b   Harel, Chava ^b   Karnieli, Eddy ^b   Pessin, Jeffrey E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Energy expenditure

Indexed keywords

CYTOCHROME P450 2E1; GLUCOSE; INSULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENERGY EXPENDITURE; FAT INTAKE; FOOD INTAKE; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HYPERLIPIDEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIPID DIET; LOCOMOTION; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SOLEUS MUSCLE; WEIGHT GAIN;

ADIPOSE TISSUE, WHITE; ANIMALS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 CYP2E1; CYTOKINES; DIET, HIGH-FAT; FATTY LIVER; GLUCOSE; GLUCOSE INTOLERANCE; HYPERLIPIDEMIAS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MUSCLE FIBERS, SKELETAL; OBESITY; SIGNAL TRANSDUCTION;

EID: 84857350273     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00258.2011     Document Type: Article

References (44)

1. Abdelmegeed MA, Carruthers NJ, Woodcroft KJ, Kim SK, Novak RF. Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes. J Pharmacol Exp Ther 315: 203-213, 2005.
2. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55: 390-397, 2006.
3. Bloch-Damti A, Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal 7: 1553-1567, 2005.
4. Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 44: 27-42, 2004.
5. Caro AA, Cederbaum AI. Role of phosphatidylinositol 3-kinase/AKT as a survival pathway against CYP2E1-dependent toxicity. J Pharmacol Exp Ther 318: 360-372, 2006.
6. Cederbaum AI, Wu D, Mari M, Bai J. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic Biol Med 31: 1539-1543, 2001.
7. Dai Y, Cederbaum AI. Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells. J Pharmacol Exp Ther 273: 1497-1505, 1995.
8. DeFuria J, Bennett G, Strissel KJ, Perfield JW 2nd, Milbury PE, Greenberg AS, Obin MS. Dietary blueberry attenuates whole-body insulin resistance in high fat-fed mice by reducing adipocyte death and its inflammatory sequelae. J Nutr 139: 1510-1516, 2009.
9. Ekstrom G, Ingelman-Sundberg M. Rat liver microsomal NADPHsupported oxidase activity and lipid peroxidation dependent on ethanolinducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 38: 1313-1319, 1989.
10. Fukuda T, Imai Y, Komori M, Nakamura M, Kusunose E, Satouchi K, Kusunose M. Different mechanisms of regioselection of fatty acid hydroxylation by laurate (omega-1)-hydroxylating P450s, P450 2C2 and P450 2E1. J Biochem 115: 338-344, 1994.
11. Gonzalez FJ. The 2006 Bernard B Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 35: 1-8, 2007.
12. Gorsky LD, Koop DR, Coon MJ. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction J Biol Chem 259: 6812-6817, 1984.
13. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 168-179, 1991.
14. Hannah JS, Howard BV. Dietary fats, insulin resistance, diabetes. J Cardiovasc Risk 1: 31-37, 1994.
15. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 16: 709-731, 2002.
16. Ji G, Yang Q, Hao J, Guo L, Chen X, Hu J, Leng L, Jiang Z. Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol 2011.
17. Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 25: 1136-1143, 2010.
18. Kathirvel E, Morgan K, French SW, Morgan TR. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 21: 973-983, 2009.
19. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 6: 724-730, 1992.
20. Laethem RM, Balazy M, Falck JR, Laethem CL, Koop DR. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcoholinducible cytochrome P450 2E1. J Biol Chem 268: 12912-12918, 1993.
21. Lavau M, Fried SK, Susini C, Freychet P. Mechanism of insulin resistance in adipocytes of rats fed a high-fat diet. J Lipid Res 20: 8-16, 1979.
22. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271: 12063-12067, 1996.
23. Luo ZC, Xiao L, Nuyt AM. Mechanisms of developmental programming of the metabolic syndrome and related disorders. World J Diabetes 1: 89-98, 2010.
24. Oberley LW. Free radicals and diabetes. Free Radic Biol Med 5: 113-124, 1988.
25. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219-246, 2010.
26. Porubsky PR, Battaile KP, Scott EE. Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. J Biol Chem 285: 22282-22290, 2010.
27. Raza H, Prabu SK, Robin MA, Avadhani NG. Elevated mitochondrial cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin- induced diabetic rats: tissue-specific variations and roles in oxidative stress. Diabetes 53: 185-194, 2004.
28. Roy U, Joshua R, Stark RL, Balazy M. Cytochrome P450/NADPHdependent biosynthesis of 5,6-trans-epoxyeicosatrienoic acid from 5,6- trans-arachidonic acid. Biochem J 390: 719-727, 2005.
29. Rudich A, Ben-Romano R, Etzion S, Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 183: 75-88, 2005.
30. Saito H, Ohi H, Sugata E, Murayama N, Fujita Y, Higuchi S. Purification and characterization of a cytochrome P450 from liver microsomes of Xenopus laevis. Arch Biochem Biophys 345: 56-64, 1997.
31. Schattenberg JM, Wang Y, Rigoli RM, Koop DR, Czaja MJ. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology 39: 444-455, 2004.
32. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 280: 9887-9894, 2005.
33. Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 71: 1036-1040, 1990.
34. Storlien LH, Baur LA, Kriketos AD, Pan DA, Cooney GJ, Jenkins AB, Calvert GD, Campbell LV. Dietary fats and insulin action. Diabetologia 39: 621-631, 1996.
35. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346, 2005.
36. Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun 11: 145-156, 2010.
37. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55: 77-85, 2003.
38. Wu D, Cederbaum AI. Removal of glutathione produces apoptosis and necrosis in HepG2 cells overexpressing CYP2E1. Alcohol Clin Exp Res 25: 619-628, 2001.
39. Yang CS, Yoo JS, Ishizaki H, Hong JY. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 22: 147-159, 1990.
40. Yoshinari K, Sato T, Okino N, Sugatani J, Miwa M. Expression and induction of cytochromes p450 in rat white adipose tissue. J Pharmacol Exp Ther 311: 147-154, 2004.
41. Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, Cohen SD, Gonzalez FJ. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 152: 193-199, 1998.
42. Zhang W, Lu D, Dong W, Zhang L, Zhang X, Quan X, Ma C, Lian H. Expression of CYP2E1 increases oxidative stress and induces apoptosis of cardiomyocytes in transgenic mice. FEBS J 278: 1484-1492, 2011.
43. Zong H, Bastie CC, Xu J, Fassler R, Campbell KP, Kurland IJ, Pessin JE. Insulin resistance in striated muscle-specific integrin receptor beta1-deficient mice. J Biol Chem 284: 4679-4688, 2009.
44. Zong H, Wang CC, Vaitheesvaran B, Kurland IJ, Hong W, Pessin JE. Enhanced energy expenditure, glucose utilization, and insulin sensitivity in VAMP8 null mice. Diabetes 60: 30-38, 2011.